Leuconostoc mesenteroides subsp. Mesenteroides YWN-1 with effects of benefiting qi, nourishing blood and enhancing immunity and application thereof
By providing Leuconostoc mesenteroides subsp. YWN-1 and its preparations, the problem of Leuconostoc mesenteroides enhancing immunity and improving qi deficiency has been solved, achieving significant effects in improving qi and blood deficiency and enhancing immunity.
Patent Information
- Application Number
- CN202511374545.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-25
- Publication Date
- 2025-11-18
AI Technical Summary
In the current technology, there are no reports on the effects of Leuconostoc mesenteroides on enhancing immunity and improving qi deficiency, and the problems of qi and blood deficiency and decreased immunity caused by long-term sleep deprivation have not been effectively solved.
A strain of Leuconostoc mesenteroides subsp. YWN-1 (CGMCC No. 34608) and its formulation are provided. Through specific culture media and formulations, including MRS medium, the supernatant after centrifugation contains a rich composition. Through specific cultures, it is prepared into a lyophilized powder for use in food, fermented products, health foods or drugs for replenishing qi and blood and enhancing immunity.
It significantly improves immune organ damage caused by qi and blood deficiency, increases the number of red blood cells, hemoglobin and platelets, enhances immunity, increases phagocytic index, serum hemolysin content and immune factor IgG and IgM content, improves symptoms of qi and blood deficiency, and enhances immunity.
Smart Images
Figure CN120966709A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of microbial engineering technology, specifically relating to Leuconostoc mesenteroides subsp. YWN-1, which has the effects of replenishing qi and blood and enhancing immunity, and its applications. Background Technology
[0002] Staying up late refers to remaining awake for extended periods at night. Statistics show that 73% of people get less than 8 hours of sleep per night, and 47% fall asleep after midnight, with the figure reaching 52% among university students. Staying up late not only involves going to bed late but is also usually accompanied by insufficient overall sleep time, incomplete or complete sleep deprivation, and other problems.
[0003] Traditional Chinese medicine believes that nighttime belongs to Yin, a crucial period for the body to "nourish Yin and blood." Staying up late disrupts the balance of "Yang entering and Yin," leading to depletion of Yin and blood, and preventing Qi and blood from fully recovering at night. Long-term sleep deprivation can cause symptoms of Qi and blood deficiency such as dry mouth and dizziness. Modern medicine believes that the body's circadian rhythm regulates the activity of immune cells, such as T cells and NK cells. Long-term sleep deprivation inhibits melatonin secretion, leading to decreased immune cell function and weakened ability to clear viruses and bacteria. Furthermore, insufficient sleep promotes the release of pro-inflammatory cells such as IL-6 and TNF-α, triggering chronic low-grade inflammation. Chronic inflammation further depletes immune resources and weakens the immune system's defensive capabilities.
[0004] Probiotics are beneficial microorganisms that are generally safer than medications. They are typically live microorganisms obtained through natural fermentation or culture, and have fewer side effects on the human body. Even with long-term use, they are less likely to cause drug resistance or side effects. While some literature reports that probiotics can improve immunity, there are currently no reports on the effects of *Enterobacterium tumefaciens* on enhancing immunity and improving qi deficiency. Summary of the Invention
[0005] Therefore, the purpose of this invention is to provide a Leuconostoc mesenteroides subsp. YWN-1 strain, which has the effect of improving blood and qi deficiency and enhancing immunity and resistance.
[0006] To achieve the above objectives, the technical content of the present invention is as follows:
[0007] On the one hand, the present invention provides a strain of Leuconostoc mesenteroides subsp. mesenteroides YWN-1, which has the accession number CGMCC No. 34608.
[0008] On the other hand, the present invention provides a culture obtained by inoculating Leuconostoc mesenteroides subsp. YWN-1 into a culture medium and culturing it.
[0009] Preferably, the culture medium includes, but is not limited to, MRS medium, M17 medium, PDA medium, LB medium, TB medium, SOB medium, TPY medium, modified TJA medium, modified MC medium, and YCFA medium.
[0010] Further preferably, the culture medium used in this invention is MRS culture medium; its composition and preparation method are as follows: 10g peptone, 5g beef extract powder, 4g yeast extract powder, 20g glucose, 1g Tween-80, 2g dipotassium hydrogen phosphate, 5g sodium acetate, 2g triammonium citrate, 0.2g magnesium sulfate (MgSO4·7H2O), 0.5g manganese sulfate (MnSO4·4H2O), 1L distilled water, pH 6.2±0.2, sterilized at 121℃ for 15min.
[0011] Preferably, the culture obtained from the culture medium includes fermentation broth of Leuconostoc mesenteroides subsp. YWN-1, fermentation supernatant of Leuconostoc mesenteroides subsp. YWN-1, fermentation broth precipitate of Leuconostoc mesenteroides subsp. YWN-1, live bacteria, and inactivated bacterial cells.
[0012] Specifically, the fermentation broth refers to the liquid produced after inoculating the microbial strain into a culture medium and culturing it.
[0013] Specifically, the supernatant of the fermentation broth refers to the clear liquid at the top of the fermentation broth after centrifugation, which contains abundant metabolic products from the bacterial growth and reproduction process, as well as some bacterial cell fragments.
[0014] Specifically, the fermentation broth precipitation refers to the liquid precipitate after centrifugation, including free proteins, residual bacterial cells, broken cells, and culture medium residues.
[0015] Specifically, the live bacteria, also known as active bacteria, can colonize and multiply in the intestines, which helps increase the number of beneficial bacteria.
[0016] Specifically, the inactivated bacterial cells refer to bacterial cells that retain their original structure and characteristics through special techniques, but no longer have the ability to grow and reproduce; these are metabiotics.
[0017] On the other hand, the present invention provides a probiotic preparation comprising the above-mentioned Leuconostoc mesenteroides subsp. YWN-1 or the culture obtained by the above-mentioned culture method.
[0018] Preferably, the probiotic preparation can be liquid, solid, or semi-solid; more preferably, the probiotic preparation is in solid form; and even more preferably, the solid form is lyophilized powder.
[0019] On the other hand, the present invention provides the application of the above-mentioned Leuconostoc mesenteroides subsp. YWN-1 or its culture or probiotic preparation in the preparation of qi-tonifying and blood-nourishing products.
[0020] On the other hand, the present invention provides the application of the above-mentioned Leuconostoc mesenteroides subsp. YWN-1 or its culture or probiotic preparation in products that enhance immunity.
[0021] Preferably, the product is food, fermented product, health food, or medicine.
[0022] Specifically, the product also includes food- or pharmaceutically acceptable excipients; the excipients are selected from one or more combinations of protectants, fillers, antacids, stabilizers, binders, lubricants, emulsifiers, thickeners, sweeteners, and flavorings.
[0023] More specifically, the food or pharmaceutically acceptable excipients include one or more of the following: lactose, microcrystalline cellulose, xanthan gum, fructooligosaccharides, galactooligosaccharides, maltodextrin, inulin, sodium carboxymethyl cellulose, lecithin, sodium alginate, pectin, gum arabic, magnesium stearate, starch, and lactose.
[0024] Preferably, the bacterial activity of Leuconostoc mesenteroides subsp. YWN-1 in the product is 1×10⁻⁶. 8 -1×10 10 CFU / mL or 1×10 8 -1×10 10 CFU / g.
[0025] More preferably, the bacterial activity of Leuconostoc mesenteroides subsp. YWN-1 in the product is 1×10⁻⁶. 9 CFU / mL or 1×10 9 CFU / g.
[0026] In another aspect, the present invention provides a composition for regulating qi and blood or enhancing immunity, the composition comprising the above-mentioned Leuconostoc mesenteroides subsp. YWN-1 or its culture or probiotic preparation.
[0027] Preferably, the bacterial activity of *Leuconostoc mesenteroides* subsp. *enteroides* in the composition is 1 × 10⁻⁶. 8 -1×10 10 CFU / mL or 1×10 8 -1×10 10 CFU / g.
[0028] More preferably, the bacterial activity of *Leuconostoc mesenteroides* subsp. *enteroides* in the composition is 1 × 10⁻⁶. 9 CFU / mL or 1×10 9 CFU / g.
[0029] Compared with the prior art, the present invention has the following advantages: 1. The Leuconostoc mesenteroides subsp. YWN-1 provided by the present invention can significantly improve the damage to the immune organs thymus and spleen caused by insufficient qi and blood.
[0030] 2 The Leuconostoc mesenteroides subsp. YWN-1 provided by this invention can significantly increase the number of red blood cells, hemoglobin and platelets in mice with qi and blood deficiency, and can improve the symptoms of qi and blood deficiency, thus achieving the effect of replenishing qi and nourishing blood.
[0031] 3 The Leuconostoc mesenteroides subsp. YWN-1 provided by this invention can significantly improve the phagocytic index, serum hemolysin content, half-hemolysis value, and the content of immune factors IgG and IgM in mice with low immunity, thus having the effect of improving immunity and resistance.
[0032] Preservation Instructions
[0033] Biomaterial: YWN-1;
[0034] Accession number: CGMCC No. 34608;
[0035] Classification and nomenclature: Leuconostoc mesenteroides subsp. mesenteroides;
[0036] Preservation period: May 21, 2025;
[0037] Preservation institution: China General Microbiological Culture Collection Center, China Committee on the Preservation and Management of Microbial Culture Collections;
[0038] Abbreviation of depositary institution: CGMCC;
[0039] Address: No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing Attached Figure Description
[0040] Figure 1 Sequencing image of the pheS gene of Leuconostoc mesenteroides subsp. YWN-1
[0041] Figure 2 Figure showing the effect of Leuconostoc mesenteroides subsp. YWN-1 on the body weight of immunocompromised mice. Detailed Implementation
[0042] The following non-limiting embodiments are intended to enable those skilled in the art to gain a more comprehensive understanding of the present invention, but do not limit the invention in any way. The following content is merely an exemplary description of the scope of protection claimed by the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, and such changes should also fall within the scope of protection claimed by the present invention.
[0043] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in the invention, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0044] The present invention will be further described below with reference to specific embodiments. Where specific experimental steps or conditions are not specified in the embodiments, they can be performed according to the conventional steps or conditions described in the literature in this field. All reagents, unless otherwise specified, are obtainable through conventional commercial channels.
[0045] Experimental Example 1: Screening, Isolation and Identification of Bacterial Strains
[0046] The strain involved in this invention was isolated and screened from brine soaking water, with the number YWN-1. It was identified by the Institute of Microbiology, Chinese Academy of Sciences as *Leuconostoc mesenteroides* subsp. *mesenteroides*. Its cell morphology and physicochemical experimental results are shown in Table 1, and the pheS gene sequencing results are shown in [Table 1]. Figure 1 .
[0047] Table 1. Results of cell morphology and physicochemical experiments
[0048]
[0049] Experimental Example 2: Preparation of a suspension of Leuconostoc mesenteroides subsp. YWN-1
[0050] This invention provides a strain of Leuconostoc mesenteroides subsp. YWN-1, which was deposited on May 21, 2025, at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 34608.
[0051] Single *Leuconostoc mesenteroides* subsp. *enteroides* YWN-1 was inoculated into MRS liquid medium and cultured at 37°C for 24 h, activating for two generations. Subsequently, it was inoculated into liquid MRS medium and enriched at 37°C for 20 h to obtain the fermentation broth. The fermentation broth was centrifuged at 8000g for 8 min, and the precipitate was collected as bacterial sludge. This sludge was washed three times with sterile physiological saline and then collected. The bacterial sludge was resuspended in sterile 30% (v / v) glycerol to obtain a live bacterial suspension, and its concentration was adjusted to 1×10⁻⁶. 9 CFU / mL.
[0052] The composition and preparation method of the MRS liquid culture medium are as follows: 10g peptone, 5g beef extract powder, 4g yeast extract powder, 20g glucose, 1g Tween 80, 2g dipotassium hydrogen phosphate, 5g sodium acetate, 2g triammonium citrate, 0.2g magnesium sulfate (MgSO4·7H2O), 0.5g manganese sulfate (MnSO4·4H2O), 1L distilled water, pH 6.2±0.2, sterilized at 121℃ for 15min.
[0053] Example 3: Preparation of Lyophilized Powder of Leuconostoc mesenteroides subsp. YWN-1
[0054] Single *Leuconostoc mesenteroides* subsp. *enteroides* YWN-1 was inoculated into MRS liquid medium and cultured at 37°C for 24 h, activating for two generations. Subsequently, it was inoculated into liquid MRS medium and enriched at 37°C for 20 h to obtain the fermentation broth. The resulting fermentation broth was centrifuged at 8000 g for 8 min, and the precipitate was collected to obtain bacterial sludge. A protectant solvent (1:3 mass ratio of bacterial sludge to protectant) (10 kg skim milk powder, 3 kg trehalose, 0.25 kg MnSO4, 4 kg sucrose, and 1000 L distilled water) was added to the bacterial sludge. The mixture was vortexed to uniformly suspend the bacteria in the protectant. The prepared bacterial resuspension was then frozen in an ultra-low temperature freezer for 12 h, followed by freeze-drying in a vacuum freeze dryer at -50°C for 24 h, yielding a viable count of 1.0 × 10⁻⁶. 9 Freeze-dried bacterial powder of Leuconostoc mesenteroides subsp. YMN-1, CFU / g.
[0055] Experiment Example 4: Effects of Leuconostoc mesenteroides subsp. YWN-1 on mice with qi and blood deficiency
[0056] The sample to be tested in the experimental group was a suspension of Leuconostoc mesenteroides subsp. YWN-1 prepared in Experiment Example 2, with a bacterial activity of 1×10⁻⁶. 9 CFU / mL.
[0057] The positive control sample was Bazhen Granules, approval number: National Medicine Approval Number Z33020294, manufactured by Ningbo Lihua Pharmaceutical Co., Ltd. (10 bags * 3.5g).
[0058] 1. Experimental animals: SPF-grade KM mice (purchased from Hunan Silek Experimental Animal Co., Ltd.), half male and half female, weighing 18±2g, were acclimatized for one week. The room temperature was maintained at 20-25℃ and the relative humidity at 50%-60%. The light and dark were alternated every 12h / 12h. The mice could drink water and eat freely.
[0059] 2. Model Establishment: Mice fed for one week were randomly divided into four groups: a blank control group, a model group, an experimental group, and a positive control group, with 10 mice in each group. Except for the blank control group, 0.3 to 0.5 mL of blood was collected from the orbital sinus of each mouse on days 1, 3, 5, 7, and 9. On days 2, 4, 6, and 8, each mouse was intraperitoneally injected with cyclophosphamide at 80, 40, 40, and 40 mg / kg, respectively (the mice were fasted for 12 hours before injection, but water was allowed). The blank control group was injected intraperitoneally with the same volume of physiological saline. The condition of the mice was observed after the last administration on day 9: Except for the blank control group, the mice in the other groups were less active, preferred quiet during the day, were lethargic, liked to curl up in corners, had bald and thin fur that was easy to fall out, had yellow and dull tails, and were weak in the limbs. They gradually showed decreased appetite and weight loss. These results indicated that the model of qi and blood deficiency was successfully established.
[0060] 3. Administration: Mice in the successfully modeled group were given 910 mg / kg of Bazhen Granules per group according to their body weight, while mice in the experimental group were given 1×10 mg / kg of Bazhen Granules per group. 9 CFU / mL 0.1 mL of the Leuconostoc mesenteroides subsp. YWN-1 suspension prepared in Example 1 was administered; the blank control group and the model group were given an equal volume (0.1 mL) of physiological saline by gavage for 10 consecutive days.
[0061] The oral dose of Bazhen Granules is 7g per day according to the instructions. Based on the equivalent dose ratio calculated by body surface area between humans and animals, the oral dose for mice is 910mg / kg.
[0062] 4-indicator detection
[0063] 4.1 Determination of organ indices in mice
[0064] Two hours after the last administration, the mice were sacrificed. Before sacrifice, the mice were weighed, and the necks were broken to kill them. The thymus and spleen were removed, the surrounding adipose tissue was quickly removed, cleaned, dried with filter paper, and weighed. The thymus index and spleen index were calculated.
[0065] Immune organ index (mg / g) = Immune organ weight (mg) / Body weight (g)
[0066] The specific results are shown in Table 2.
[0067] Table 2 Results of Immune Organ Index Measurement
[0068]
[0069] Note: Compared with the blank control group, ## indicates P<0.01, # indicates P<0.05; compared with the model group, && indicates P<0.01, & indicates P<0.01.
[0070] 4.2 Determination of complete blood count in mice
[0071] After the last administration, blood was collected by enucleation, 100 μL from each eye. The whole blood was kept in anticoagulation tubes and the red blood cells (RBC), hemoglobin (HGB), and platelets (PLT) were measured using an automated blood cell analyzer.
[0072] The specific results are shown in Table 3.
[0073] Table 3. Results of routine blood tests and serum tests
[0074]
[0075] Note: Compared with the blank control group, ## indicates P<0.01, # indicates P<0.05; compared with the model group, && indicates P<0.01, & indicates P<0.01.
[0076] 5 Results Analysis
[0077] Immune organs in the immune system are divided into central immune organs and peripheral immune organs. In this invention, the immune organs we selected mainly include the thymus and spleen. The indicators of these immune organs generally reflect the immune status of the body. As shown in Table 2, the thymus index and spleen index in the model group were significantly lower than those in the blank control group (P < 0.01), indicating successful modeling. Compared with the model group, the thymus index and spleen index in the experimental group were significantly higher, indicating that the *Enteromorpha spp.* subsp. *enteromorpha* provided in this invention has a significant inhibitory effect on damage to the thymus and spleen caused by qi and blood deficiency.
[0078] Complete blood count (CBC) is an objective indicator of peripheral blood cell morphology. Table 3 shows that RBC, HGB, and PLT in the model group were significantly lower than in the blank control group, indicating successful establishment of the Qi and Blood Deficiency mouse model. Compared to the model group, the RBC in the experimental group was significantly higher, with no significant difference compared to the positive and blank control groups. The HGB and PLT in the experimental group were significantly different from those in the model group, indicating that the *Leuconostoc mesenteroides* subsp. *enteroides* YMN-1 provided in this invention has a significant improving effect on peripheral blood in mice with Qi and Blood Deficiency, possessing the efficacy of replenishing Qi and nourishing blood.
[0079] Experimental Example 5: Effects of Leuconostoc mesenteroides subsp. YWN-1 on immunocompromised mice.
[0080] 1. Experimental animals: Female Balb / c mice (weight 18±2g), SPF grade, acclimatized for one week, with room temperature maintained at 20-25℃ and relative humidity at 50%-60%, and 12h / 12h light and dark alternation, and the mice were allowed free access to water and food.
[0081] 2. Grouping and gavage dosage: Mice were randomly divided into 4 groups: blank control group, model group, experimental group and positive control group, with 30 mice in each group. Among them, 10 mice in each group were used for carbon clearance test, 10 mice were used for serum hemolysin test, and 10 mice were used for serum detection.
[0082] For the first 7 days, the model group, experimental group, and positive control group were all injected intraperitoneally with cyclophosphamide 30 mg / kg / day. Starting on the 8th day, the model group was administered 0.1 mL of physiological saline by gavage, and the experimental group was administered 0.1 mL of a bacterial suspension of Leuconostoc mesenteroides subsp. YWN-1 prepared in Example 1 (bacterial activity 1×10⁻⁶). 9 The positive control group was given levamisole hydrochloride 40 mg / kg / day by gavage, while the blank control group was given an equal volume of physiological saline by gavage. Both groups were fed continuously for 21 days, during which time the animals had free access to food and water.
[0083] On day 16 of feeding, a serum hemolysin test was performed. Blood was collected in centrifuge tubes, serum was collected, and the half-maximal hemolysin value was calculated. On day 20 of feeding, a carbon clearance test was performed. Mice were euthanized, and the liver and spleen were removed, weighed, and their weights calculated. The remaining 10 mice were observed for body weight. After 21 days of feeding, the mice were fasted for 12 hours, anesthetized, and blood was collected by enucleation. The blood was centrifuged to obtain serum for the determination of immune factors.
[0084] 3. Detection Indicators
[0085] 3.1 Changes in mouse body weight
[0086] During the experiment, body weight was measured every 3 days (i.e., 1d, 4d, 7d, 10d, 13d, 16d, 19d, and 21d), and weight changes were recorded. The results are as follows: Figure 2 As shown. By Figure 2 It was found that cyclophosphamide injection reduced the body weight of mice, but after day 8, the body weight of the experimental group, model group, and positive control group began to increase, and from day 16 onwards, the body weight of the experimental group began to exceed that of the model group. This indicates that the *Leuconostoc mesenteroides* subsp. *mianopteris* YMN-1 provided by this invention has a positive effect on the weight recovery of immunocompromised mice.
[0087] 3.2 Mouse carbon clearance experiment
[0088] On the twentieth day of the experiment, mice were injected via the tail vein with Indian ink diluted four times with physiological saline (10 mL / kg). At 2 and 10 minutes after injection, 20 μL of blood was drawn from the internal canthal venous plexus and added to 2 mL of 0.1% Na2CO3 solution. The OD value was measured at 600 nm. The mice were then sacrificed, and their livers and spleens were removed and weighed.
[0089] The phagocytic index, representing the carbon clearance capacity of mice, is calculated using the following formula:
[0090]
[0091]
[0092] OD1: OD value of blood at t1; OD2: OD value of blood at t2.
[0093] Carbon clearance capacity is an important indicator for evaluating the body's immune function, mainly reflecting the activity of phagocytes. The results are shown in Table 4. As can be seen from the table, the carbon clearance phagocytic index of the model group was significantly lower than that of the blank control group. Compared with the model group, the carbon clearance phagocytic index of the experimental group and the positive control group was significantly higher. This indicates that the Leuconostoc mesenteroides subsp. YMN-1 provided by this invention can improve the carbon particle phagocytic capacity of immunocompromised mice and can improve the immunity of mice to a certain extent.
[0094] Table 4. Phagocytic Index Results
[0095]
[0096] Note: Compared with the model group, && indicates P < 0.01, and & indicates P < 0.01.
[0097] 3.4 Changes in mouse serum hemolysin
[0098] HC50% hemolysis rate 50 The assay was performed using an ELISA reader. Specifically, on day 16, mice in each group were intraperitoneally injected with 0.2 mL of 2% (v / v) sheep red blood cell suspension (SRBC). On day 21, blood was collected in centrifuge tubes, and serum was collected. Sample wells and blank wells were prepared. For sample wells, 50 μL of serum diluted 100-fold with SA buffer was added. For blank wells, 50 μL of SA buffer was added to each well, followed by 25 μL of 10% (v / v) SRBC and 50 μL of complement (diluted 1:8 with SA solution). The mixture was incubated at 37°C for 30 min, then placed on ice to terminate the reaction. The plates were centrifuged at 1500 rpm for 10 min. 50 μL of the supernatant from each well was added to a 96-well plate, along with 150 μL of DuPont's reagent. Simultaneously, half-hemolysis wells were prepared, with 12.5 μL of 10% (v / v) SRBC added, and DuPont's reagent added to a final volume of 200 μL. Mix thoroughly on a shaker, let stand for 10 min, and then measure the optical density of each well at 540 nm using an automated microplate reader. The amount of hemolysin is expressed as the half-hemolysis value (HC50).
[0099]
[0100] HC 50It is an indicator for detecting the overall activity of the classical complement pathway and can indirectly reflect complement-mediated immune defense function. If HC 50 The decrease indicates reduced activity of the classical complement pathway, a specific type of immunodeficiency. Table 5 shows that, compared to the model group, the experimental group had significantly lower HC levels. 50 The levels of *Leuconostoc mesenteroides* subsp. *mianopsis* YMN-1 provided by this invention are significantly increased and show a significant difference compared to the blank control group, indicating that the levels of serum hemolysin in immunocompromised mice can be increased and immunity can be improved.
[0101] Table 5 Results of the half-maximal hemolysis value
[0102]
[0103] Note: Compared with the blank control group, ## indicates P<0.01, # indicates P<0.05; compared with the model group, && indicates P<0.01, & indicates P<0.01.
[0104] 3.5 Immune Factor Detection
[0105] The obtained serum was tested to determine the levels of IgG and IgM. The specific testing methods were performed according to the instructions of the Immunoglobulin G (IgG) Kit (Lianke Biotechnology EK271) and Immunoglobulin M (IgM) Kit (Lianke Biotechnology EK276). The specific results are shown in Table 6.
[0106] Table 6 Results of Immune Factor Detection
[0107]
[0108] Note: Compared with the blank control group, ## indicates P<0.01, # indicates P<0.05; compared with the model group, && indicates P<0.01, & indicates P<0.01.
[0109] IgG is a major immunoglobulin in body fluids, accounting for approximately 70%-75% of the total immunoglobulins in the blood. It plays an important role in binding complement, enhancing the phagocytosis of pathogens by immune cells, and neutralizing bacterial toxins. Immunoglobulin M (IgM) is the largest immunoglobulin in molecular weight, mainly synthesized by plasma cells in the spleen and lymph nodes. It is mainly distributed in serum, existing in pentamer form, accounting for 5%-10% of total serum Ig. IgM has strong bactericidal, complement-activating, immunomodulatory, and agglutinating effects, and also participates in the pathological processes of certain autoimmune diseases and hypersensitivity reactions. As shown in Table 6, compared with the blank control group, both IgG and IgM decreased significantly in the model group, indicating that the immunodeficiency mouse model was successfully established. Compared with the model group, the experimental group showed a significant improvement with a highly significant difference, while there was no significant difference compared with the blank control group. This indicates that the Leuconostoc mesenteroides subsp. YWN-1 provided by this invention has the ability to enhance the IgM and IgG immunoglobulins in immunocompromised mice, thereby enhancing immunity.
[0110] In summary, the Leuconostoc mesenteroides subsp. YWN-1 provided by this invention can improve the spleen index and liver index of mice with qi and blood deficiency; improve the number of red blood cells, hemoglobin and platelets in serum; and has the effect of improving the immunity and blood deficiency of mice with qi and blood deficiency. It can be applied to products that improve qi and blood deficiency.
[0111] It can also improve the carbon clearance phagocytic index, serum hemolysin and half-hemolysin value, and the content of immune factors IgG and IgM in mice with low immunity, thus enhancing immunity and can be applied to products that improve immunity / resistance.
[0112] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.
Claims
1. A subsp. *Leuconostoc mesenteroides*, characterized in that, The Leuconostoc mesenteroides subspecies is YWN-1, with accession number CGMCC No. 34608.
2. A culture, characterized in that, The culture was obtained by culturing Leuconostoc mesenteroides subsp. YWN-1 as described in claim 1.
3. A probiotic preparation, characterized in that, The probiotic preparation comprises Leuconostoc mesenteroides subsp. YWN-1 as described in claim 1 or the culture as described in claim 2.
4. The application of Leuconostoc mesenteroides subsp. YWN-1 according to claim 1, or the culture according to claim 2, or the probiotic preparation according to claim 3 in the preparation of qi-tonifying and blood-nourishing products.
5. The use of Leuconostoc mesenteroides subsp. YWN-1 according to claim 1, or the culture according to claim 2, or the probiotic preparation according to claim 3 in the preparation of products that enhance immunity.
6. The application according to claim 4 or 5, characterized in that, The product is a fermented product, health food, or medicine.
7. The application according to claim 4 or 5, characterized in that, The bacterial activity of Leuconostoc mesenteroides subsp. YWN-1 in the product was 1×10⁻⁶. 8 -1×10 10 CFU / mL or 1×10 8 -1×10 10 CFU / g.
8. A composition for replenishing qi and blood or enhancing immunity, characterized in that, The composition comprises Leuconostoc mesenteroides subsp. YWN-1 as described in claim 1, or the culture as described in claim 2, or the probiotic preparation as described in claim 3.
9. The composition according to claim 8, characterized in that, The bacterial activity of Leuconostoc mesenteroides subsp. YWN-1 in the composition was 1×10⁻⁶. 8 -1×10 10 CFU / mL or 1×10 8 -1×10 10 CFU / g.